Kinase inhibitors: the road ahead

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

The protein kinase complement of the human genome

Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy

Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,153 · see citing works

Control of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+

Bootman, M. D., Missiaen, L., Parys, J. B., SMEDT, H. D., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120 · see citing works

XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor

Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00611-0 · Cited by 4,054 · see citing works

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works

Super-enhancers in the control of cell identity and disease

Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · see citing works

An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress

Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M. A., Sadri, N., Yun, C., Popko, B., Paules, R. S., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00105-9 · Cited by 3,336 · see citing works

Toll-Like Receptor Signaling Pathways

Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,250 · see citing works

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · see citing works

IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA

Calfon, M. A., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., & Ron, D. (2002) · Nature · doi:10.1038/415092a · Cited by 2,826 · see citing works

Targeting cancer with small molecule kinase inhibitors

Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,585 · see citing works

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · see citing works

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,711 · see citing works

Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae

Ficarro, S. B., McCleland, M. L., Stukenberg, P. T., Burke, D. J., Ross, M. M., Shabanowitz, J., Hunt, D. F., & White, F. M. (2002) · Nature Biotechnology · doi:10.1038/nbt0302-301 · Cited by 1,636 · see citing works

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · see citing works

Combining immunotherapy and targeted therapies in cancer treatment

Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,583 · see citing works

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Dürr, A., Bressman, S., Brice, A., Aasly, J. O., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,523 · see citing works

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,252 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works

Mechanisms and consequences of Jak–STAT signaling in the immune system

Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221 · see citing works

Transcriptional Addiction in Cancer

Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,188 · see citing works

Tracking cancer drugs in living cells by thermal profiling of the proteome

Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187 · see citing works

The regulation of protein function by multisite phosphorylation – a 25 year update

Cohen, P. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01712-6 · Cited by 1,138 · see citing works

PI3Kγ is a molecular switch that controls immune suppression

Kaneda, M. M., Messer, K., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,118 · see citing works

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., Tessarollo, L., Casellas, R. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.033 · Cited by 1,075 · see citing works

GPCRdb: an information system for G protein-coupled receptors

Ísberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A. S., Vroling, B., Bojarski, A. J., Vriend, G., & Gloriam, D. E. I. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1178 · Cited by 1,067 · see citing works

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060 · see citing works

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

Copeland, R. A. (2005) · PubMed · Cited by 1,045 · see citing works

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Böesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,036 · see citing works

Mechanisms of Age-Related Macular Degeneration

Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,029 · see citing works

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Fleischmann, R., Kremer, J. M., Cush, J. J., Schulze‐Koops, H., Connell, C. A., Bradley, J. D., Gruben, D. C., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,028 · see citing works

Proteome-wide covalent ligand discovery in native biological systems

Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940 · see citing works

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · see citing works

Immunobiology of the TAM receptors

Lemke, G., & Rothlin, C. V. (2008) · Nature reviews. Immunology · doi:10.1038/nri2303 · Cited by 867 · see citing works

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

Kwiatkowski, N. P., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B. M., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 865 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Henau, O. D., Rausch, M. P., Winkler, D. A., Campesato, L. F., Liu, C., Hirschhorn-Cymerman, D., Budhu, S., Ghosh, A., Pink, M. M., Tchaicha, J. H., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 862 · see citing works

The target landscape of clinical kinase drugs

Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · see citing works

IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates

Han, D., Lerner, A. G., Walle, L. V., Upton, J.-P., Xu, W., Hagen, A., Backes, B. J., Oakes, S. A., & Papa, F. R. (2009) · Cell · doi:10.1016/j.cell.2009.07.017 · Cited by 816 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 768 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding

Young, T. K., Abel, R., Kim, B., Berne, B. J., & Friesner, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610202104 · Cited by 697 · see citing works

Role of the Active-Site Solvent in the Thermodynamics of Factor Xa Ligand Binding

Abel, R., Young, T. K., Farid, R., Berne, B. J., & Friesner, R. A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja0771033 · Cited by 682 · see citing works

Small‐Molecule PROTACS: New Approaches to Protein Degradation

Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674 · see citing works

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 669 · see citing works

Developing Irreversible Inhibitors of the Protein Kinase Cysteinome

Liu, Q., Sabnis, Y. A., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 662 · see citing works

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648 · see citing works

Computational methods in drug discovery

Leelananda, S. P., & Lindert, S. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.267 · Cited by 647 · see citing works

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N. P., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C. M., Altabef, A. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631 · see citing works

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1 H -indol-5-yl)-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Axten, J. M., Medina, J. R., Feng, Y., Shu, A. Y. L., Romeril, S. P., Grant, S. W., Li, W. H. H., Heerding, D. A., Minthorn, E. A., Mencken, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300713s · Cited by 620 · see citing works

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice

Moreno, J. A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J. M., Ortori, C. A., Willis, A. E., Fischer, P. M., Barrett, D. A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006767 · Cited by 589 · see citing works

On the mechanism of sensing unfolded protein in the endoplasmic reticulum

Credle, J. J., Finer-Moore, J. S., Papa, F. R., Stroud, R. M., & Walter, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509487102 · Cited by 589 · see citing works

Sulfonyl fluorides as privileged warheads in chemical biology

Narayanan, A., & Jones, L. H. (2015) · Chemical Science · doi:10.1039/c5sc00408j · Cited by 554 · see citing works

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552 · see citing works

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Katayama, R., Khan, T. M., Benes, C. H., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 546 · see citing works

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W. P., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T. C., Maecker, H. L., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 530 · see citing works

Screening out irrelevant cell-based models of disease

Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · see citing works

Redox-based reagents for chemoselective methionine bioconjugation

Lin, S., Yang, X., Jia, S., Weeks, A. M., Hornsby, M. J., Lee, P. S., Nichiporuk, R. V., Iavarone, A. T., Wells, J. A., Toste, F. D., et al. (2017) · Science · doi:10.1126/science.aal3316 · Cited by 511 · see citing works

Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells.

Hann, S., & Eisenman, R. N. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.11.2486 · Cited by 503 · see citing works

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Harris, P. A., Berger, S. B., Jeong, J. U., Nagilla, R., Bandyopadhyay, D., Campobasso, N., Capriotti, C. A., Cox, J. A., Dare, L. C., Dong, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01751 · Cited by 502 · see citing works

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 496 · see citing works

Allosteric Inhibition of the IRE1α RNase Preserves Cell Viability and Function during Endoplasmic Reticulum Stress

Ghosh, R., Wang, L., Wang, E. S., Perera, B. G. K., Igbaria, A., Morita, S., Prado, K. B., Thamsen, M., Caswell, D. R., Macias, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.002 · Cited by 488 · see citing works

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456 · see citing works

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

Christensen, C. L., Kwiatkowski, N. P., Abraham, B. J., Carretero, J., Al‐Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 440 · see citing works

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437 · see citing works

Targeting Plasmodium PI(4)K to eliminate malaria

McNamara, C. W., Lee, M., Lim, C. S., Lim, S. H., Roland, J. T., Nagle, A. S., Simon, O., Yeung, B. K. S., Chatterjee, A. K., McCormack, S., et al. (2013) · Nature · doi:10.1038/nature12782 · Cited by 435 · see citing works

Prolonged and tunable residence time using reversible covalent kinase inhibitors

Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 428 · see citing works

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Yang, C., Li, Z., Bhatt, T., Dickler, M. N., Giri, D. D., Scaltriti, M., Baselga, J. M., Rosen, N. X., & Chandarlapaty, S. (2016) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 413 · see citing works

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407 · see citing works

PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?

Rommel, C., Camps, M., & Ji, H. (2007) · Nature reviews. Immunology · doi:10.1038/nri2036 · Cited by 403 · see citing works

Macrophages and Dendritic Cells Use Different Axl/Mertk/Tyro3 Receptors in Clearance of Apoptotic Cells

Seitz, H., Camenisch, T. D., Lemke, G., Earp, H. S., & Matsushima, G. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5635 · Cited by 403 · see citing works

Signaling cell death from the endoplasmic reticulum stress response

Shore, G. C., Papa, F. R., & Oakes, S. A. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.11.003 · Cited by 403 · see citing works

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

Pelish, H. E., Liau, B. B., Nitulescu, I. I., Tangpeerachaikul, A., Poss, Z. C., Silva, D. H. D., Caruso, B., Arefolov, A., Fadeyi, O., Christie, A. L., et al. (2015) · Nature · doi:10.1038/nature14904 · Cited by 397 · see citing works

A Perspective on the Kinetics of Covalent and Irreversible Inhibition

Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392 · see citing works

Molecular neurobiology of mTOR

Switon, K., Kotulska, K., Janusz, A., Zmorzyńska, J., & Jaworski, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 389 · see citing works

Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes

Zhao, Q., Ouyang, X., Wan, X., Gajiwala, K. S., Kath, J. C., Jones, L. H., Burlingame, A. L., & Taunton, J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08536 · Cited by 388 · see citing works

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000500 · Cited by 382 · see citing works

Kinase Drug Discovery – What’s Next in the Field?

Cohen, P., & Alessi, D. R. (2012) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 378 · see citing works

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378 · see citing works

The crystal structure of human IRE1 luminal domain reveals a conserved dimerization interface required for activation of the unfolded protein response

Zhou, J., Liu, C. Y., Back, S. H., Clark, R. L., Peisach, D., Xu, Z., & Kaufman, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606480103 · Cited by 375 · see citing works

Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient Mice

Berger, S. B., Kasparcova, V., Hoffman, S., Swift, B., Dare, L., Schaeffer, M., Capriotti, C., Cook, M., Finger, J., Hughes-Earle, A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400499 · Cited by 374 · see citing works

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374 · see citing works

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367 · see citing works

Enzyme Inhibitor Discovery by Activity-Based Protein Profiling

Niphakis, M. J., & Cravatt, B. F. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035708 · Cited by 366 · see citing works

A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors

Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T., Joslyn, C. M., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 361 · see citing works

In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases

Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E. S., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 357 · see citing works

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Ciceri, P., Müller, S., O’Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C. D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 345 · see citing works

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 344 · see citing works

Activity-based protein profiling for biochemical pathway discovery in cancer

Nomura, D. K., Dix, M. M., & Cravatt, B. F. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2901 · Cited by 342 · see citing works

Thermal proteome profiling monitors ligand interactions with cellular membrane proteins

Reinhard, F. B. M., Eberhard, D., Werner, T., Franken, H., Childs, D., Doce, C., Savitski, M. F., Huber, W. K., Bantscheff, M., Savitski, M. M., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3652 · Cited by 310 · see citing works

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01921 · Cited by 309 · see citing works

Drug repositioning for Alzheimer's disease

Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

Wollenhaupt, J., Silverfield, J. C., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D. C., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301 · see citing works

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Rao, V. K., Webster, S., Dalm, V. A. S. H., Šedivá, A., van Hagen, P. M., Holland, S. M., Rosenzweig, S. D., Christ, A. D., Sloth, B., Cabanski, M., et al. (2017) · Blood · doi:10.1182/blood-2017-08-801191 · Cited by 297 · see citing works

Translational value of mouse models in oncology drug development

Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293 · see citing works

The (un)targeted cancer kinome

Fedorov, O., Müller, S., & Knapp, S. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.297 · Cited by 293 · see citing works

CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA Wild-Type and mutated models of Triple-Negative breast Cancer

Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291 · see citing works

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802470 · Cited by 290 · see citing works

PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia

Radford, H. E., Moreno, J. A., Verity, N., Halliday, M., & Mallucci, G. R. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1487-z · Cited by 289 · see citing works

DNA-Encoded Library Screening Identifies Benzo[ b ][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

Harris, P. A., King, B. W., Bandyopadhyay, D., Berger, S. B., Campobasso, N., Capriotti, C. A., Cox, J. A., Dare, L. C., Dong, X., Finger, J. N., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01898 · Cited by 289 · see citing works

Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C., Hartnett, J. R., Ingold, M. R., Zimmerman, K., Machleidt, T., Kirkland, T. A., Huwiler, K. G., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.10.010 · Cited by 285 · see citing works

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281 · see citing works

The ins and outs of selective kinase inhibitor development

Müller, S., Chaikuad, A., Gray, N. S., & Knapp, S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1938 · Cited by 276 · see citing works

Covalent docking of large libraries for the discovery of chemical probes

London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274 · see citing works

Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions

Greggio, E., & Cookson, M. (2009) · ASN NEURO · doi:10.1042/an20090007 · Cited by 274 · see citing works

Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis

Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 267 · see citing works

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

Winkler, D. G., Faia, K. L., DiNitto, J. P., Ali, J. A., White, K., Brophy, E. E., Pink, M. M., Proctor, J., Lussier, J., Martin, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.017 · Cited by 262 · see citing works

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 261 · see citing works

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257 · see citing works

The Cysteinome of Protein Kinases as a Target in Drug Development

Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707875 · Cited by 237 · see citing works

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

Stokes, J. B., Adair, S. J., Slack‐Davis, J. K., Walters, D. M., Tilghman, R. W., Hershey, E. D., Lowrey, B. T., Thomas, K. S., Bouton, A. H., Hwang, R. F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0261 · Cited by 233 · see citing works

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

Ember, S. W., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 227 · see citing works

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

Gharwan, H., & Groninger, H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 225 · see citing works

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Evans, E. K., Tester, R. W., Aslanian, S., Karp, R., Sheets, M. P., Labenski, M., Witowski, S. R., Lounsbury, H. A., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 223 · see citing works

Dysregulation of the basal RNA polymerase transcription apparatus in cancer

Bywater, M. J., Pearson, R. B., McArthur, G. A., & Hannan, R. D. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3496 · Cited by 223 · see citing works

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds

Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 222 · see citing works

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)

Robb, C. M., Contreras, J. I., Kour, S., Taylor, M., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 221 · see citing works

High-throughput kinase profiling as a platform for drug discovery

GOLDSTEIN, D. M., Gray, N. S., & Zarrinkar, P. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2541 · Cited by 219 · see citing works

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh‐hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 215 · see citing works

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

Myers, S. H., Brunton, V. G., & Unciti‐Broceta, A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 210 · see citing works

Targeting protein kinases for the development of anti-inflammatory drugs

Cohen, P. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.015 · Cited by 207 · see citing works

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 207 · see citing works

Pharmacological targeting of the pseudokinase Her3

Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205 · see citing works

Overview of CDK9 as a target in cancer research

Morales, F., & Giordano, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1138186 · Cited by 200 · see citing works

Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12248 · Cited by 199 · see citing works

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199 · see citing works

Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors

Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., & Taunton, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401221b · Cited by 196 · see citing works

Measuring and interpreting the selectivity of protein kinase inhibitors

Smyth, L. A., & Collins, I. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0023-9 · Cited by 195 · see citing works

Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing

Liang, K., Gao, X., Gilmore, J. M., Florens, L. A., Washburn, M. P., Smith, E. R., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 194 · see citing works

Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G., Capelletti, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1671 · Cited by 192 · see citing works

Mechanisms of drug resistance in kinases

Barouch‐Bentov, R., & Sauer, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.546344 · Cited by 187 · see citing works

Protein Kinase Inhibitors as a Therapeutic Modality

Levitzki, A. (2003) · Accounts of Chemical Research · doi:10.1021/ar0201207 · Cited by 178 · see citing works

Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs

Hines, J. F., Gough, J. D., Corson, T. W., & Crews, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217206110 · Cited by 177 · see citing works

Vinyl sulfone: a versatile function for simple bioconjugation and immobilization

Morales‐Sanfrutos, J., López-Jaramillo, J., Ortega‐Muñoz, M., Megía-Fernández, A., Pérez-Balderas, F., Mateo, F. H., & Santoyo‐González, F. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b920576d · Cited by 177 · see citing works

Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations

Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11467 · Cited by 177 · see citing works

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease

West, A. B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.019 · Cited by 177 · see citing works

KLIFS: a structural kinase-ligand interaction database

Kooistra, A. J., Kanev, G. K., van Linden, O. P. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1082 · Cited by 176 · see citing works

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications

Diaz-Montero, C. M., Finke, J. H., & Montero, A. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.003 · Cited by 173 · see citing works

Structure of the compact lumenal domain of yeast Ire1

Credle, J. J., Finer-Moore, J. S., Papa, F. R., Stroud, R. M., & Walter, P. (2005) · Worldwide Protein Data Bank · doi:10.2210/pdb2be1/pdb · Cited by 173 · see citing works

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

Bahjat, F. R., Pine, P. R., Reitsma, A. J., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23428 · Cited by 171 · see citing works

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn, M., Sun, J., Lee, S., Ahn, J. S., & Park, K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300656 · Cited by 169 · see citing works

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

Sonawane, Y. A., Taylor, M., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00150 · Cited by 164 · see citing works

Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Lee, K. L., Ambler, C. M., Anderson, D. R., Boscoe, B. P., Bree, A. G., Brodfuehrer, J., Chang, J. S., Choi, C., Chung, S., Curran, K. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00231 · Cited by 164 · see citing works

Receptor Tyrosine Kinases and Targeted Cancer Therapeutics

Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159 · see citing works

Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases

Caraux, A., Lu, Q., Fernandez, N. C., Riou, S., Santo, J. P. D., Raulet, D. H., Lemke, G., & Roth, C. (2006) · Nature Immunology · doi:10.1038/ni1353 · Cited by 157 · see citing works

Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells

Huang, S., Li, Y., Zhang, J., Rong, J., & Ye, S. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.789905 · Cited by 154 · see citing works

Progress towards a public chemogenomic set for protein kinases and a call for contributions

Drewry, D. H., Wells, C. I., Andrews, D. M., Angell, R. M., Al‐Ali, H., Axtman, A. D., Capuzzi, S. J., Elkins, J. M., Ettmayer, P., Frederiksen, M. U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181585 · Cited by 154 · see citing works

Small‐Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153 · see citing works

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

Evans, C. A., Liu, T., Lescarbeau, A., Nair, S. J., Grenier, L., Pradeilles, J. A., Glenadel, Q., Tibbitts, T. T., Rowley, A. M., DiNitto, J. P., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00238 · Cited by 153 · see citing works

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism

Lu, H., Xue, Y., Yu, G. K., Arias, C., Lin, J., Fong, S. K., Faure, M., Weisburd, B., Ji, X., Mercier, A., et al. (2015) · eLife · doi:10.7554/elife.06535 · Cited by 152 · see citing works

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Scott, J. D., DeMong, D. E., Greshock, T. J., Basu, K., Dai, X., Harris, J. M., Hruza, A. W., Li, S. W., Lin, S., Liu, H. S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00045 · Cited by 149 · see citing works

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

Dale, T. C., Clarke, P. A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.-J., Mallinger, A., Samant, R. S., Czodrowski, P., Müsil, D., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1952 · Cited by 147 · see citing works

Explaining why Gleevec is a specific and potent inhibitor of Abl kinase

Lin, Y.-L., Meng, Y., Jiang, W., & Roux, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214330110 · Cited by 146 · see citing works

Proteasome Activation by Small Molecules

Leestemaker, Y., de Jong, A., Witting, K. F., Penning, R., Schuurman, K. G., Rodenko, B., Zaal, E. A., van de Kooij, B., Laufer, S., Heck, A. J. R., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.010 · Cited by 144 · see citing works

Proteins Encoded by the Human c-myc Oncogene: Differential Expression in Neoplastic Cells

Hann, S., & Eisenman, R. N. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.11.2486-2497.1984 · Cited by 143 · see citing works

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

Crofford, L. J., Nyhoff, L. E., Sheehan, J. H., & Kendall, P. L. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1152888 · Cited by 142 · see citing works

Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species

Wani, R., Qian, J. X., Yin, L.-M., Bechtold, E., King, S. B., Poole, L. B., Paek, E., Tsang, A. W., & Furdui, C. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011665108 · Cited by 141 · see citing works

Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase

Vona, C. D., Bezdan, D., Islam, A. B. M. M. K., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.026 · Cited by 137 · see citing works

Animal models of CNS disorders

McGonigle, P. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.016 · Cited by 135 · see citing works

Identification and Characterization of an Irreversible Inhibitor of CDK2

Anscombe, E., Meschini, E., Mora-Vidal, R., Martin, M. P., Staunton, D., Geitmann, M., Danielson, U. H., Stanley, W. A., Wang, L.-Z., Reuillon, T. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.018 · Cited by 134 · see citing works

The half-life of c-myc mRNA in growing and serum-stimulated cells: influence of the coding and 3' untranslated regions and role of ribosome translocation.

Herrick, D., & Ross, J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2119 · Cited by 132 · see citing works

CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance

Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.012 · Cited by 132 · see citing works

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Förster, M., Chaikuad, A., Bauer, S. M., Holstein, J., Robers, M. B., Corona, C. R., Gehringer, M., Pfaffenrot, E., Ghoreschi, K., Knapp, S., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.008 · Cited by 132 · see citing works

Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling

Médard, G., Pachl, F., Ruprecht, B., Klaeger, S., Heinzlmeir, S., Helm, D., Qiao, H., Ku, X., Wilhelm, M., Kuehne, T., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr5012608 · Cited by 131 · see citing works

Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition

Dalton, S. E., Dittus, L., Thomas, D. A., Convery, M. A., Nunes, J., Bush, J. T., Evans, J. P., Werner, T., Bantscheff, M., Murphy, J. A., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08979 · Cited by 126 · see citing works

Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters

Robinson, D. D., Sherman, W., & Farid, R. (2010) · ChemMedChem · doi:10.1002/cmdc.200900501 · Cited by 125 · see citing works

Thermodynamic Contributions of the Ordered Water Molecule in HIV-1 Protease

Li, Z., & Lazaridis, T. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0299203 · Cited by 124 · see citing works

High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors

Miduturu, C. V., Deng, X., Kwiatkowski, N. P., Yang, W., Brault, L., Filippakopoulos, P., Chung, E., Yang, Q., Schwaller, J., Knapp, S., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.010 · Cited by 124 · see citing works

IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation

Cheong, J. K., Hung, N. T., Wang, H., Tan, P. B. O., Voorhoeve, P. M., Lee, S. H., & Virshup, D. M. (2011) · Oncogene · doi:10.1038/onc.2010.627 · Cited by 123 · see citing works

Non-kinase targets of protein kinase inhibitors

Munoz, L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.266 · Cited by 123 · see citing works

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors

Hoegenauer, K., Soldermann, N., Zécri, F. J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00293 · Cited by 123 · see citing works

Mycobacterium tuberculosis Serine/Threonine Protein Kinases

Prisic, S., & Husson, R. (2014) · Microbiology spectrum · doi:10.1128/microbiolspec.mgm2-0006-2013 · Cited by 122 · see citing works

Directly targeting transcriptional dysregulation in cancer

Gonda, T. J., & Ramsay, R. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4018 · Cited by 119 · see citing works

RNA Polymerase II Transcription Elongation Control

Guo, J., & Price, D. H. (2013) · Chemical Reviews · doi:10.1021/cr400105n · Cited by 117 · see citing works

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain

Richards, M. W., Law, E. W. P., Rennalls, L. P., Busacca, S., O’Regan, L., Fry, A. M., Fennell, D. A., & Bayliss, R. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322892111 · Cited by 115 · see citing works

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis

Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301553 · Cited by 113 · see citing works

Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay

Merget, B., Turk, S., Eid, S., Rippmann, F., & Fulle, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01611 · Cited by 112 · see citing works

Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease

Batson, J., Toop, H. D., Redondo, C., Babaei‐Jadidi, R., Chaikuad, A., Wearmouth, S., Gibbons, B., Allen, C., Tallant, C., Zhang, J., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01048 · Cited by 110 · see citing works

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

Heffron, T. P., Ndubaku, C. O., Salphati, L., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00005 · Cited by 109 · see citing works

Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors

Klaeger, S., Gohlke, B.-O., Perrin, J., Gupta, V., Heinzlmeir, S., Helm, D., Qiao, H., Bergamini, G., Handa, H., Savitski, M. M., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01063 · Cited by 108 · see citing works

Strategically targeting MYC in cancer

Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 107 · see citing works

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Yin, T., Lallena, M. J., Kreklau, E. L., Fales, K. R., Carballares, S., Torrres, R., Wishart, G. N., Ajamie, R. T., Cronier, D. M., Iversen, P. W., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0849 · Cited by 104 · see citing works

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

Burger, J. A. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0188-8 · Cited by 100 · see citing works

Oncogenic signaling of MEK5-ERK5

Hoang, V. T., Yan, T. J., Cavanaugh, J. E., Flaherty, P. T., Beckman, B. S., & Burow, M. E. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.034 · Cited by 100 · see citing works

Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis

Borgel, D., Clauser, S., Bornstain, C., Bièche, I., Bissery, A., Remones, V., Fagon, J.-Y., Aiach, M., & Diehl, J. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000195014.56254.8a · Cited by 96 · see citing works

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730 · see citing works

An atlas of substrate specificities for the human serine/threonine kinome

Johnson, J. L., Yaron, T. M., Huntsman, E. M., Kerelsky, A., Song, J., Regev, A., Lin, T.-Y., Liberatore, K., Cizin, D. M., Cohen, B. M., et al. (2023) · Nature · doi:10.1038/s41586-022-05575-3 · Cited by 728 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

COVID-19 infection and rheumatoid arthritis: Faraway, so close

Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454 · see citing works

Kinase inhibition in autoimmunity and inflammation

Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431 · see citing works

Targeting innate immune mediators in type 1 and type 2 diabetes

Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416 · see citing works

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293 · see citing works

PROTACs: A novel strategy for cancer therapy

Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186 · see citing works

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs

Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159 · see citing works

Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders

Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148 · see citing works

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase

Zhao, Q., Ren, C., Liu, L., Chen, J., Shao, Y., Sun, N., Sun, R., Kong, Y., Ding, X., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01264 · Cited by 134 · see citing works

Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders

Hanzl, A., Casement, R., Imrichova, H., Hughes, S. J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01177-2 · Cited by 133 · see citing works

A comprehensive review of SHP2 and its role in cancer

Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119 · see citing works

Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?: Miniperspective

De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110 · see citing works

Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor

Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103 · see citing works

Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications

Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86 · see citing works

Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes

Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61 · see citing works

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence

Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50 · see citing works

Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery

Bernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01030 · Cited by 49 · see citing works

Targeting dementias through cancer kinases inhibition

Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43 · see citing works

Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine

Du, G., Rao, S., Gurbani, D., Henning, N. J., Jiang, J., Che, J., Yang, A., Ficarro, S. B., Marto, J. A., Aguirre, A. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01502 · Cited by 39 · see citing works

Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases

Pham, A.-T., Ghilardi, A. F., & Sun, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1127722 · Cited by 40 · see citing works

Tau‑targeting multifunctional nanocomposite based on tannic acid-metal for near-infrared fluorescence/magnetic resonance bimodal imaging-guided combinational therapy in Alzheimer's disease

Gu, Y., Zhang, Q., Huang, H., Ho, K. H. W., Zhang, Y., Yi, C., Zheng, Y., Chang, R. C. C., Wang, E. S., & Yang, M. (2024) · Theranostics · doi:10.7150/thno.98462 · Cited by 27 · see citing works

Evolutionary crossroads of cell signaling: PP1 and PP2A substrate sites in intrinsically disordered regions

Hoermann, B., & Köhn, M. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200175 · Cited by 14 · see citing works

TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells

Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R. (2022) · Advanced Biology · doi:10.1002/adbi.202200030 · Cited by 14 · see citing works

Antibody-enabled small-molecule drug discovery

Lawson, A. D. G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3756 · Cited by 80 · see citing works

RNA‐Selective Small‐Molecule Ligands: Recent Advances in Live‐Cell Imaging and Drug Discovery

Chan, K. H., Wang, Y., Zheng, B., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202300271 · Cited by 10 · see citing works

Current Status and Strategy of Middle-Molecule Drug Discovery

Hidenori, M. (2022) · Proceedings for Annual Meeting of The Japanese Pharmacological Society · doi:10.1254/jpssuppl.95.0_2-s23-3

Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery

Schreiber, S. L. (2000) · Science · doi:10.1126/science.287.5460.1964 · Cited by 2,571 · see citing works

Design of Tracers in Fluorescence Polarization Assay for Extensive Application in Small Molecule Drug Discovery

Hua, L., Wang, D., Wang, K., Wang, Y., Gu, J., Zhang, Q., You, Q., & Wang, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00881 · Cited by 33 · see citing works